Promis Neurosciences (PMN) Stock Forecast & Price Target $10.98 +0.13 (+1.20%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$10.98 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Promis Neurosciences - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 4 Analyst RatingsSell1Hold0Buy3 Based on 4 Wall Street analysts who have issued ratings for Promis Neurosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a sell rating, 2 have given a buy rating, and 1 has given a strong buy rating for PMN. Consensus Price Target $26.50141.35% Upside According to the 4 analysts' twelve-month price targets for Promis Neurosciences, the average price target is $26.50. The highest price target for PMN is $35.00, while the lowest price target for PMN is $18.00. The average price target represents a forecasted upside of 141.35% from the current price of $10.98. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for PMN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Promis Neurosciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMN Analyst Ratings Over TimeTypeCurrent Forecast5/24/25 to 5/24/261 Month Ago4/24/25 to 4/24/263 Months Ago2/23/25 to 2/23/261 Year Ago5/24/24 to 5/24/25Strong Buy1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)3 Buy rating(s)3 Buy rating(s)2 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$26.50$42.67$42.67$112.50Forecasted Upside141.35% Upside279.60% Upside170.21% Upside791.09% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyBuy PMN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History PMN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Promis Neurosciences Stock vs. The CompetitionTypePromis NeurosciencesMedical CompaniesBroader MarketConsensus Rating Score 2.75 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside141.35% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent PMN NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/20/2026Brookline Capital MarketsNot Rated UpgradeStrong-Buy2/6/2026 Guggenheim5 of 5 starsEddie Hickman3 of 5 starsLower TargetBuy$125.00 ➝ $35.00+164.05%1/22/2026 Weiss RatingsNot Rated Reiterated RatingSell (E+)12/1/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRaghuram SelvarajuSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$4.00 ➝ $18.00+175.44%7/21/2025 Leede FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeModerate Buy5/12/2025 Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJason McCarthySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$75.00+504.47%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:59 PM ET. PMN Forecast - Frequently Asked Questions What is Promis Neurosciences' forecast for 2026? According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Promis Neurosciences is $26.50, with a high forecast of $35.00 and a low forecast of $18.00. Should I buy or sell Promis Neurosciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Promis Neurosciences in the last year. There is currently 1 sell rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PMN shares. Does Promis Neurosciences's stock price have much upside? According to analysts, Promis Neurosciences's stock has a predicted upside of 141.35% based on their 12-month stock forecasts. Has Promis Neurosciences been upgraded by Wall Street analysts recently? Over the previous 90 days, Promis Neurosciences's stock had 1 upgrade by analysts. What analysts cover Promis Neurosciences? Promis Neurosciences has been rated by research analysts at Brookline Capital Markets in the past 90 days. Do Wall Street analysts like Promis Neurosciences more than its competitors? Analysts like Promis Neurosciences more than other "medical" companies. The consensus rating for Promis Neurosciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how PMN compares to other companies. Stock Forecasts and Research Tools Related Companies OVID Stock Forecast AVIR Stock Forecast PBYI Stock Forecast SNDL Stock Forecast IRD Stock Forecast CMPX Stock Forecast GLSI Stock Forecast IMRX Stock Forecast ORGO Stock Forecast SRZN Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Promis Neurosciences RecommendationsBrookline Capital MarketsWall Street ZenGuggenheimWeiss RatingsHC WainwrightLeede Financial This page (NASDAQ:PMN) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
